WHO ICTRP trial
Montelukast effect in patients with chronic obstructive pulmonary disease
IRCT20190423043361N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20190423043361N1 |
|---|---|
| Public title | Montelukast effect in patients with chronic obstructive pulmonary disease |
| Scientific title | The effect of montelukast on the serum levels of inflammatory factors in patients with chronic obstructive pulmonary disease (COPD) in intervention and control groups |
| Primary sponsor | Khoram-Abad University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 4 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Chronic Obstructive Pulmonary Disease. Other chronic obstructive pulmonary disease |
| Interventions | Intervention 1: Intervention group: In one cycle of treatment the patients receives 10 mg of montelukast, Poursina factory production, once a day for two months. Intervention 2: Control group: The same placebo, Poursina factory production… |
| Registration date | Aug 26, 2019 |
| Target size | 74 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: